Dyne's z-basivarsen shows 4.8% muscle strength improvement at one year in DM1 trial, signaling potential clinical benefit in a...

Giredestrant cuts disease progression risk 44% in ER-positive breast cancer versus standard endocrine therapy in phase III evERA trial...

Moleculin closed Part A enrollment at 89 subjects in its pivotal AML MIRACLE trial. Here's what site directors and...

A double-blind tACS trial targeting theta oscillations in methamphetamine patients sets a new design standard regulators will use to...

EDC query automation improves data quality only when sites can respond without being overwhelmed by low-value queries.

Federal government outlines four regulatory changes for IRB oversight affecting multisite studies, protocol reviews, and institutional compliance by 2027.

NewAmsterdam Pharma doses first participant in SPINOZA Phase 2b trial of obicetrapib for preclinical Alzheimer's disease, testing a CETP...

Iopofosine I 131 achieved 79% major response in BTK inhibitor-refractory Waldenström macroglobulinemia patients in Phase 2b trial data.

Vanda's tasimelteon meets Phase III endpoint in delayed sleep-wake disorder, advancing 60% of patients' sleep onset by 30+ minutes...

AbbVie's zumilokibart met all primary endpoints in Phase 2 atopic dermatitis testing, showing rapid skin and itch improvement with...